Recently updated guidelines from the U.S. Preventive Services Task Force (USPSTF) have substantially expanded the pool of individuals for whom breast cancer susceptibility gene (BRCA)-related cancer risk assessment is warranted. But does the update go far enough?

Patients with newly recurrent breast cancer who carry a germline BRCA1 or BRCA2 mutation are about twice as likely as noncarriers to have central nervous system involvement, finds a single-center retrospective cohort study. And carrying a BRCA2 mutation independently predicts such involvement and death from the disease.